Last reviewed · How we verify

nucleoside analogue sparing HAART regimen

Danish HIV Research Group · FDA-approved active Small molecule

nucleoside analogue sparing HAART regimen is a Antiretroviral regimen (protease inhibitor + NNRTI combination) Small molecule drug developed by Danish HIV Research Group. It is currently FDA-approved for HIV-1 infection (treatment-naive or treatment-experienced patients).

A nucleoside analogue-sparing antiretroviral regimen uses protease inhibitors and/or non-nucleoside reverse transcriptase inhibitors to suppress HIV replication without the toxicity associated with nucleoside reverse transcriptase inhibitors.

A nucleoside analogue-sparing antiretroviral regimen uses protease inhibitors and/or non-nucleoside reverse transcriptase inhibitors to suppress HIV replication without the toxicity associated with nucleoside reverse transcriptase inhibitors. Used for HIV-1 infection (treatment-naive or treatment-experienced patients).

At a glance

Generic namenucleoside analogue sparing HAART regimen
SponsorDanish HIV Research Group
Drug classAntiretroviral regimen (protease inhibitor + NNRTI combination)
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhaseFDA-approved

Mechanism of action

This regimen strategy avoids nucleoside analogues (NRTIs) such as AZT, which are associated with mitochondrial toxicity, lipodystrophy, and metabolic complications. Instead, it relies on alternative drug classes—typically a ritonavir-boosted protease inhibitor combined with a non-nucleoside reverse transcriptase inhibitor (NNRTI)—to achieve viral suppression while reducing long-term toxicity burden.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about nucleoside analogue sparing HAART regimen

What is nucleoside analogue sparing HAART regimen?

nucleoside analogue sparing HAART regimen is a Antiretroviral regimen (protease inhibitor + NNRTI combination) drug developed by Danish HIV Research Group, indicated for HIV-1 infection (treatment-naive or treatment-experienced patients).

How does nucleoside analogue sparing HAART regimen work?

A nucleoside analogue-sparing antiretroviral regimen uses protease inhibitors and/or non-nucleoside reverse transcriptase inhibitors to suppress HIV replication without the toxicity associated with nucleoside reverse transcriptase inhibitors.

What is nucleoside analogue sparing HAART regimen used for?

nucleoside analogue sparing HAART regimen is indicated for HIV-1 infection (treatment-naive or treatment-experienced patients).

Who makes nucleoside analogue sparing HAART regimen?

nucleoside analogue sparing HAART regimen is developed and marketed by Danish HIV Research Group (see full Danish HIV Research Group pipeline at /company/danish-hiv-research-group).

What drug class is nucleoside analogue sparing HAART regimen in?

nucleoside analogue sparing HAART regimen belongs to the Antiretroviral regimen (protease inhibitor + NNRTI combination) class. See all Antiretroviral regimen (protease inhibitor + NNRTI combination) drugs at /class/antiretroviral-regimen-protease-inhibitor-nnrti-combination.

What development phase is nucleoside analogue sparing HAART regimen in?

nucleoside analogue sparing HAART regimen is FDA-approved (marketed).

What are the side effects of nucleoside analogue sparing HAART regimen?

Common side effects of nucleoside analogue sparing HAART regimen include Lipid elevation (cholesterol, triglycerides), Gastrointestinal disturbance, Hepatotoxicity, Rash (NNRTI-related), Hyperglycemia.

Related